Biocon receives EC marketing authorisation for pertuzumab biosimilar
Biocon announced that the European Commission (EC) has granted marketing authorization for Pebrilzo?, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU).
Biocon's pertuzumab biosimilar is the first biosimilar to receive EC marketing authorisation under the European Medicines Agency's (EMA) new tailored clinical approach. This milestone follows its positive CHMP opinion on September 17, 2026.
Shreehas Tambe, CEO & Managing Director, Biocon, said: ?The European Commission's approval of Pebrilzo?, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a significant regulatory milestone for Biocon. With this approval, pertuzumab becomes our fifth oncology biosimilar approved in both Europe and the United States, strengthening our global oncology portfolio and reinforcing our commitment to expanding access to high-quality, affordable biologic therapies for patients with HER2-positive breast cancer.?